DISCOVERY STREAM May 12-13
Day 1 | Day 2 | Download Stream Brochure
THURSDAY, MAY 12
12:00 pm Registration
1:30 Chairperson’s Opening Remarks
1:40 Correlating Biophysical and ADME Properties of a Protein Conjugated to Linear or Branched PEG
Yulia Vugmeyster, Principal Research Scientist, Pharmacokinetics, Dynamcs, and Metabolism, Pfizer
Modulation of pharmacokinetics (PK) profiles of therapeutic proteins by conjugation of polyethylene glycol (PEG) is widely used in the biopharmaceutical industry. We studied the effects that PEG structure and the conformation of the resulting conjugates have on the PK profile of a PEGylated protein. A therapeutic protein was conjugated to linear or two different type of branched PEGs of the same MW. Biophysical, biochemical, and ADME properties (in rodents and primates) were evaluated for all combinations of the protein-PEG conjugate. Correlation between the biopshysical and ADME profiles and species differences are discussed.
2:10 A Germline Knowledge-Based Computational Approach for Determining Antibody Complementarity Determining Regions
Shanrong Zhao, Ph.D., Researcher, In Silico Informatics, Centocor Discovery Research
Determination of complementarity determining regions (CDRs) in an antibody is essential for antibody engineering and optimization. Based upon the mapping between a mature antibody and its corresponding germline gene segments, a computational algorithm was developed for automatic determination of CDRs. The algorithm has been proven to be very fast, robust, and has been recently extended into in silico antibody engineering.
2:40 A Standardized Platform for Antibody Characterization
James P. Carney, Ph.D. Research Biologist, US Army
Sponsored by2:55 Applying Tag-lite® to Therapeutic Antibodies Screening and Characterization: A Review of Recent FindingsStéphane Martinez, Tag-lite® Product Manager, Cisbio BioassaysGPCRs and other cell surface receptors such as RTKs are privileged targets in small molecule and biotherapeutic screening. The optimization of Tag-lite® technology platform, a combination of HTRF® and self-labeling technologies for the study of cell surface biomolecule interactions, has recently boosted the way a large number of assay configurations could be set up for investigating receptor biology and pharmacology under multiple angles. This presentation will detail a number of cases studies for antibody screening and characterization, assessed through ligand binding assays, and receptor function.
3:10 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Problem Solving Breakout Sessions
Concurrent Problem Solving Breakouts are interactive sessions hosted by a moderator to discuss a topic in depth. They are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in.
TABLE: Current Stage of Modeling Antibody Structures & Antibody-Antigen Interactions
Moderator: Aroop Sircar, Ph.D., Post Doc Computational Scientist, Antibody Design, Protein Engineering and Antibody Technologies, EMD Serono
• Are structural semi-accurate models useful, how ?
• Given the current state of technology, how can structural modeling be improved?
• Pros/Cons of some of the leading antibody modeling software in the market
TABLE: The Marriage of Next Generation Sequencing(NGS) and Antibody Engineering
Moderator: Shanrong Zhao, Ph.D. In Silico Immunology, Johnson & Johnson Pharmaceutical Research & Development L.L.C.
• NGS and monoclonal antibodies isolation and discovery
• High-throughput sequencing of the antibody repertoire
• Epitope mapping (of Mycobacterium tuberculosis) by massive genome sequencing
TABLE: Application of fc Optimization to an Antibody Drug Candidate
Moderator: Greg Lazar, Ph.D., Associate Director, Protein Engineering, Xencor, Inc.
• Rationale for when to enhance effector function and/or extend half-life
• Critical parameters for technology selection
• Validation and acceptance criteria
TABLE: Trapping PIGF: How to Make a Drug that Works?
Moderator: Kristen Bower, Ph.D., Scientist, Biology CovX Research LLC.
• Some PlGF-trapping molecules have shown anti-cancer efficacy in both syngeneic and xenograft models
• Other molecules of comparable potencies have failed to demonstrate efficacy across a large panel of xenografts
• What is the relevance of the different PlGF isoforms, and how will preclinical data translate to clinical efficacy?
TABLE: Exploring the Interaction of Antibody with Its Intracellular Collaborator TRIM21
Moderator: Patricia Ng, Stem Cell and Developmental Biology, Singapore Immunology Network, A* STAR
• Antibodies that enter the cell interact with a cytoplasmic protein TRIM21
• An interaction hotspot in the Fc region of the antibody has been reported
• We explore the options with regards to the manipulation of this interaction for improved antibody function
TABLE : Antibody Characterization: Speed vs. Accuracy?Moderator: Volker Stadler, Ph.D., CEO,PEPperPRINT GmbH
• clone selection criteria
• What do you need to know about your antibody?
• a comparison of peptide mapping technologies
5:00 Close of Day
Day 1 | Day 2 | Download Stream Brochure